Last reviewed · How we verify

Formoterol Fumarate DPI

Organon and Co · Phase 2 active Small molecule

Formoterol Fumarate DPI is a Small molecule drug developed by Organon and Co. It is currently in Phase 2 development. Also known as: SCH 045571, MK-5571, Foradil® Aerolizer®.

At a glance

Generic nameFormoterol Fumarate DPI
Also known asSCH 045571, MK-5571, Foradil® Aerolizer®
SponsorOrganon and Co
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Formoterol Fumarate DPI

What is Formoterol Fumarate DPI?

Formoterol Fumarate DPI is a Small molecule drug developed by Organon and Co.

Who makes Formoterol Fumarate DPI?

Formoterol Fumarate DPI is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

Is Formoterol Fumarate DPI also known as anything else?

Formoterol Fumarate DPI is also known as SCH 045571, MK-5571, Foradil® Aerolizer®.

What development phase is Formoterol Fumarate DPI in?

Formoterol Fumarate DPI is in Phase 2.

Related